PCV 20

BIOLOGICAL6 trials

Sponsors

Inventprise Inc., GlaxoSmithKline

Conditions

ChickenpoxPneumococcal Vaccines

Phase 1

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

CompletedNCT05540028

Inventprise Inc.Pneumococcal Vaccines

Start: 2022-09-28End: 2023-07-31Updated: 2023-08-30

Phase 2

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

CompletedNCT06077656

Inventprise Inc.Pneumococcal Vaccines

Start: 2023-10-25End: 2024-05-24Updated: 2026-03-17

Phase 3

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

RecruitingNCT06693895

GlaxoSmithKlineChickenpox

Start: 2024-11-26End: 2026-11-23Target: 750Updated: 2025-01-20

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

RecruitingNCT06740630

GlaxoSmithKlineChickenpox

Start: 2025-01-10End: 2027-05-13Target: 1840Updated: 2025-03-07

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

RecruitingNCT06806137

GlaxoSmithKlineChickenpox

Start: 2025-05-15End: 2027-05-03Target: 600Updated: 2025-12-04

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

RecruitingNCT06855160

GlaxoSmithKlineChickenpox

Start: 2025-04-17End: 2027-02-02Target: 900Updated: 2025-12-04

Related Papers

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

2026-01-22